You are here: Home: Meet The Professors - Breast Cancer 1 | 2008: CME Information

Meet The Professors: A case-based discussion on the management of breast cancer in the adjuvant and metastatic settings

STATEMENT OF NEED / TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. Meet The Professors utilizes relevant case-based discussions between community oncologists and clinical investigators to help practicing clinicians incorporate this information into their management strategies for patients with breast cancer.

LEARNING OBJECTIVES

• Evaluate the clinical implications of emerging clinical trial data in breast cancer treatment, and incorporate these data into management strategies in the adjuvant, neoadjuvant, metastatic and preventive settings.
• Counsel patients who are postmenopausal with ER-positive breast cancer about the risks and benefits of adjuvant aromatase inhibitors and of switching to or sequencing aromatase inhibitors after tamoxifen.
• Talk with patients who are premenopausal about the risks and benefits of adjuvant ovarian suppression alone or with other endocrine interventions.
• Implement an algorithm for HER2 testing and treatment of patients with HER2-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
• Appraise the emerging data on various adjuvant chemotherapy approaches, including modified doses and schedules and the use of taxanes, and explain the absolute risks and benefits of adjuvant chemotherapy regimens to patients.
• Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse, and when applicable, utilize these to guide therapy decisions.
• Assess the emerging data for novel biologic and molecular-targeted therapies with clinical activity in breast cancer, and determine how these should be incorporated into the treatment algorithm for appropriate patients with metastatic disease, including patients with triple-negative tumors.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Educational Assessment and Credit Form located at www.MeetTheProfessors.com/CME. www.MeetTheProfessors.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.